



**B. NAGA BHUSHAN & Co.,**  
**CHARTERED ACCOUNTANTS**

Cell : 9849995678, 7382590368  
email : nagabhushanca@gmail.com  
bnagabhushan@yahoo.com  
1-1-380/38, Ashok Nagar Extn.,  
Hyderabad - 500 020. Telangana.

Date : 10.05.2025

## **Independent Auditor's Report**

### **To the Members of Chalasani Hospitals private limited Report on the Audit of the Financial Statements**

#### **Opinion**

We have audited the Financial Statements of **M/s Chalasani Hospitals private limited** ("the Company"), which comprise the Balance Sheet as at March 31, 2025, the Statement of Profit and Loss, Cash Flow Statement ended on that date, and a summary of significant accounting policies and other explanatory information (Hereinafter referred to as Financial Statements).

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 (the "Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2025, the profit, and its cash flows for the year ended on that date.

#### **Basis for Opinion**

We conducted our audit of the financial statements in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

#### **Information Other than the Financial Statements and Auditors' Report Thereon**

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the 'Director's report' but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.





**B. NAGA BHUSHAN & Co.,**  
**CHARTERED ACCOUNTANTS**

Cell : 9849995678, 7382590368  
email : nagabhushanca@gmail.com  
bnagabhushan@yahoo.com  
1-1-380/38, Ashok Nagar Extn.,  
Hyderabad - 500 020. Telangana.

Date : 10.05.2025

### **Independent Auditor's Report**

#### **To the Members of Chalasani Hospitals private limited Report on the Audit of the Financial Statements**

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### **Management's Responsibility for the Financial Statements**

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.





**B. NAGA BHUSHAN & Co.,**  
**CHARTERED ACCOUNTANTS**

Cell : 9849995678, 7382590368  
email : nagabhushanca@gmail.com  
bnagabhushan@yahoo.com  
1-1-380/38, Ashok Nagar Extn.,  
Hyderabad - 500 020. Telangana.

Date : 10.05.2025

### **Independent Auditor's Report**

**To the Members of Chalasani Hospitals private limited**  
**Report on the Audit of the Financial Statements**

### **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal financial control with reference to financial statements.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.





**B. NAGA BHUSHAN & Co.,**  
**CHARTERED ACCOUNTANTS**

Cell : 9849995678, 7382590368  
email :nagabhushanca@gmail.com  
bnagabhushan@yahoo.com  
1-1-380/38, Ashok Nagar Extn.,  
Hyderabad - 500 020. Telangana.

Date : 10.05.2025

**Independent Auditor's Report**

**To the Members of Chalasani Hospitals private limited**  
**Report on the Audit of the Financial Statements**

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in "Annexure A" statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
  - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.







**B. NAGA BHUSHAN & Co.,**  
**CHARTERED ACCOUNTANTS**

Cell : 9849995678, 7382590368  
email : nagabhushanca@gmail.com  
bnagabhushan@yahoo.com  
1-1-380/38, Ashok Nagar Extn.,  
Hyderabad - 500 020. Telangana.

Date : 10.05.2025

**Independent Auditor's Report**

**To the Members of Chalasani Hospitals private limited**  
**Report on the Audit of the Financial Statements**

- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- (c) The Balance Sheet, the Statement of Profit and Loss, and the Statement of Cash Flows dealt with by this Report are in agreement with the relevant books of account.
- (d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- (e) On the basis of the written representations received from the directors as on March 31, 2025 taken on record by the Board of Directors, none of the directors are disqualified as on March 31, 2025 from being appointed as a director in terms of Section 164 (2) of the Act.
- (f) With respect to the adequacy of the internal financial controls with reference to those financial statements and the operating effectiveness of such controls, refer to our separate Report in "Annexure B" to this report.
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
  - i. The Company does not have any pending litigations which would impact its financial position.
  - ii. The Company did not have any long-term contracts including derivatives contracts for which there were any material foreseeable losses.
  - iii. There were no amounts which are required to be transferred, to the Investor Education and Protection Fund by the Company as at 31st March, 2025.





**B. NAGA BHUSHAN & Co.,**  
**CHARTERED ACCOUNTANTS**

Cell : 9849995678, 7382590368  
email : nagabhushanca@gmail.com  
bnagabhushan@yahoo.com  
1-1-380/38, Ashok Nagar Extn.,  
Hyderabad - 500 020. Telangana.

Date : 10.05.2025

**Independent Auditor's Report**

**To the Members of Chalasani Hospitals private limited**  
**Report on the Audit of the Financial Statements**

- iv.
- a. The Management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) / entity(ies), including foreign entities ('Intermediaries'), with the understanding, whether recorded in writing or otherwise, that the Intermediary has, whether directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- b. The Management has represented that, to the best of its knowledge and belief, no funds have been received by the Company from any person(s) / entity(ies), including foreign entities, that the company has directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- c. Based on the audit procedures which we have considered reasonable and appropriate in the circumstances and according to the information and explanations provided to us by the Management in this regard, nothing has come to our notice that has caused us to believe that the representations made by the Management under sub-clause (a) and (b) contain any material misstatement.
- v. The Company has neither declared nor paid any dividend during the year.
- vi. As proviso to rule 3(1) of Companies (Accounts) Rules, 2014 is applicable for the company only w.e.f from April 1, 2023, reporting under this clause is applicable.





**B. NAGA BHUSHAN & Co.,**  
**CHARTERED ACCOUNTANTS**

Cell : 9849995678, 7382590368  
email : nagabhushanca@gmail.com  
bnagabhushan@yahoo.com  
1-1-380/38, Ashok Nagar Extn.,  
Hyderabad - 500 020. Telangana.

Date : 10.05.2025

**Independent Auditor's Report**

**To the Members of Chalasani Hospitals private limited**  
**Report on the Audit of the Financial Statements**

Based on our examination, the company has used accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and recording an audit trail of each and every transaction, creating an edit log of each change made in the books of account along with the date when such changes were made. The audit trail facility has been operating throughout the year for all relevant transactions recorded in the software. Further, there are no instances of audit trail feature being tampered with. Additionally, the audit trail of prior year has been preserved as per the statutory requirements for record retention.

3. In our opinion, according to information, explanations given to us, the provisions of Section 197 of the Act and the rules thereunder are not applicable to the Company as it is a private Company.

**For B. Naga Bhushan & Co.,**  
Chartered Accountants  
Firm Registration No: 005584S

*Naga Bhushan*

B. Naga Bhushan  
Partner  
Membership No: 028574  
UDIN: 25028574BMJLJG9968



Place: Hyderabad  
Date: 10.05.2025



**B. NAGA BHUSHAN & Co.,**  
**CHARTERED ACCOUNTANTS**

Cell : 9849995678, 7382590368  
email : nagabhushanca@gmail.com  
bnagabhushan@yahoo.com  
1-1-380/38, Ashok Nagar Extn.,  
Hyderabad - 500 020. Telangana.

Date : 10.05.2025

**ANNEXURE A TO INDEPENDENT AUDITORS' REPORT OF EVEN DATE ON THE  
FINANCIAL STATEMENTS OF CHALASANI HOSPITALS PRIVATE LIMITED FOR  
THE YEAR ENDED MARCH 31, 2025.**

[Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' in the Independent Auditors' Report]

i.

(a) A The company has maintained proper records showing full particulars including quantitative details and situation of Property, Plant and Equipment.

B The Company has maintained proper records showing full particulars of intangible assets.

(b) Property, Plant and Equipment have been physically verified by the management at reasonable intervals during the year and no material discrepancies were identified on such verification.

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, title deeds pertaining to the immovable properties disclosed in the financial statements are held in the name of the company.

(d) According to the information and explanations given to us, the Company has not revalued its property, plant and Equipment (including Right of Use assets) and its intangible assets. Accordingly, the requirements under paragraph 3(i)(d) of the Order are not applicable to the Company.

(e) According to the information and explanations given to us, no proceeding has been initiated or pending against the Company for holding Benami property under the Benami Transactions (Prohibition) Act, 1988 and rules made thereunder. Accordingly, the provisions stated in paragraph 3(i) (e) of the Order are not applicable to the Company.

ii. (a) According to the provisions stated in paragraph 3(ii) (a) to (b) of the Order physical verification of inventory has been conducted at reasonable intervals by the management and in the opinion of the auditor, the coverage and procedure of such verification by the management is appropriate; No discrepancies of 10% or more in the aggregate for each class of inventory were noticed







**B. NAGA BHUSHAN & Co.,**  
**CHARTERED ACCOUNTANTS**

Cell : 9849995678, 7382590368  
email : nagabhushanca@gmail.com  
bnagabhushan@yahoo.com  
1-1-380/38, Ashok Nagar Extn.,  
Hyderabad - 500 020. Telangana.

Date : 10.05.2025

- (b) The company has been sanctioned working capital limits of fifteen crore rupees from Bandhan bank on the basis of security of current assets. Quarterly statements filed by the company with the bank are in agreement with the books of account of the Company
- iii. According to the information & explanation provided to us, the Company has not made any investments, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties. Hence, the requirements under paragraph 3(iii) of the Order are not applicable to the Company.
- iv. In our opinion and according to the information and explanations given to us, the Company has not either directly or indirectly, granted any loan to any of its directors or to any other person in whom the director is interested, in accordance with the provisions of section 185 of the Act and the Company has not made investments through more than two layers of investment companies in accordance with the provisions of section 186 of the Act. Accordingly, provisions stated in paragraph 3(iv) of the Order are not applicable to the Company.
- v. In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of sections 73, 74, 75 and 76 of the Act, the rules framed thereunder and the Circulars, notifications issued from time to time with regard to the deposits accepted. No order has been passed by the Company Law Board or National Company Law Tribunal or Reserve Bank of India or any Court or any other Tribunal in this respect.
- vi. The provisions of sub-section (1) of section 148 of the Act are not applicable to the Company as the turnover doesn't meet the turnover criteria mentioned in Companies (Cost Records and Audit) Rules 2014 for maintenance of cost records. Accordingly, the provisions stated in paragraph 3 (vi) of the Order are not applicable to the Company.
- vii.  
(a) According to the information and explanations given to us and the records of the Company examined by us, in our opinion, undisputed statutory dues including goods and services tax, provident fund, employees' state insurance, income-tax, customs duty, cess have generally been regularly deposited with the appropriate authorities though there has been a slight delay in a few cases.





**B. NAGA BHUSHAN & Co.,**  
**CHARTERED ACCOUNTANTS**

Cell : 9849995678, 7382590368  
email : nagabhushanca@gmail.com  
bnagabhushan@yahoo.com  
1-1-380/38, Ashok Nagar Extn.,  
Hyderabad - 500 020. Telangana.

Date : 10.05.2025

- (b) According to the information and explanation given to us and the records of the Company examined by us, there are no dues of income tax, goods and service tax, customs duty, cess and any other statutory dues which have not been deposited on account of any dispute.
- viii. According to the information and explanations given to us, there are no transactions which are not accounted for in the books of account which have been surrendered or disclosed as income during the year in the Tax Assessment of the Company. Also, there is no previously unrecorded income which has been now recorded in the books of account. Hence, the provision stated in paragraph 3(viii) of the Order is not applicable to the Company.
- ix.
- (a) In our opinion and according to the information and explanations given to us, the Company has not defaulted on repayment of loans or borrowings or in payment of interest thereon to any lender.
- (b) According to the information and explanations given to us and on the basis of our audit procedures, we report that the company has not been declared a willful defaulter by any bank or financial institution or government or any government authority.
- (c) In our opinion, and according to the information & explanation provided to us, money raised by way of term loans during the year has been applied for the purpose for which they were raised.
- (d) In our opinion, according to the information & explanation provided to us, there are no funds raised on a short-term basis for long-term purposes. Accordingly, the provision stated in paragraph 3(ix)(d) of the Order is not applicable to the Company.
- (e) According to the information & explanation given to us and on an overall examination of the financial statements of the Company, we report that the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures.





**B. NAGA BHUSHAN & Co.,**  
**CHARTERED ACCOUNTANTS**

Cell : 9849995678, 7382590368  
email : nagabhushanca@gmail.com  
bnagabhushan@yahoo.com  
1-1-380/38, Ashok Nagar Extn.,  
Hyderabad - 500 020. Telangana.

Date : 10.05.2025

- (f) According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies.
- x.
- (a) The Company did not raise any money by way of an initial public offer or further public offer (including debt instruments) during the year. Accordingly, the provisions stated in paragraph 3 (x)(a) of the Order are not applicable to the Company.
- (b) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares fully, partly or optionally convertible debentures during the year. Accordingly, the provisions stated in paragraph 3 (x)(b) of the Order are not applicable to the Company.
- xi.
- (a) During the course of our audit, examination of the books and records of the Company, carried out in accordance with the generally accepted auditing practices in India, and according to the information and explanations given to us, we have neither come across any instance of material fraud by the Company or on the Company.
- (b) We have not come across any instance of material fraud by the Company or on the Company during the course of audit of the financial statement for the year ended March 31, 2024, accordingly the provisions stated in paragraph (xi)(b) of the Order are not applicable to the Company.
- (c) There are no whistle blower complaints against the company during the year hence the provisions stated in paragraph (xi)(c) of the Order are not applicable to the Company.
- xii. In our opinion and according to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, the provisions stated in paragraph 3(xii) (a) to (c) of the Order are not applicable to the Company.





**B. NAGA BHUSHAN & Co.,**  
**CHARTERED ACCOUNTANTS**

Cell : 9849995678, 7382590368  
email : nagabhushanca@gmail.com  
bnagabhushan@yahoo.com  
1-1-380/38, Ashok Nagar Extn.,  
Hyderabad - 500 020. Telangana.

Date : 10.05.2025

- xiii. According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with sections 177 and 188 of the Act, where applicable and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- xiv. According to the information and explanations given to us, the company has an internal audit system commensurate with the size and nature of its business. Since the company is not mandated as per Companies (Accounts) Rules, 2014 to appoint an Internal Auditor, the Company does not require to comply with the provision of section 138 of the Act. Hence, the provisions stated in paragraph 3(xiv) (a) to (b) of the Order are not applicable to the Company.
- xv. According to the information and explanations given to us, in our opinion during the year the Company has not entered into non-cash transactions with directors or people connected with its directors and hence provisions of section 192 of the Act are not applicable to the company. Accordingly, the provisions stated in paragraph 3(xv) of the Order are not applicable to the Company.
- xvi.
- (a) In our opinion, the Company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions stated in paragraph clause 3 (xvi)(a) of the Order are not applicable to the Company.
- (b) In our opinion, the Company has not conducted any Non-Banking Financial or Housing Finance activities without any valid Certificate of Registration from Reserve Bank of India. Hence, the reporting under paragraph clause 3 (xvi)(b) of the Order is not applicable to the Company
- (c) The Company is not a Core investment Company (CIC) as defined in the regulations made by Reserve Bank of India. Hence, the reporting under paragraph clause 3 (xvi)(c) of the Order is not applicable to the Company.
- (d) The Company does not have more than one CIC as a part of its group. Hence, the provisions stated in paragraph clause 3 (xvi)(d) of the Order are not applicable to the Company.








**B. NAGA BHUSHAN & Co.,**  
**CHARTERED ACCOUNTANTS**

Cell : 9849995678, 7382590368  
email : nagabhushanca@gmail.com  
bnagabhushan@yahoo.com  
1-1-380/38, Ashok Nagar Extn.,  
Hyderabad - 500 020. Telangana.

Date : 10.05.2025

- xvii. According to the information & explanation provided to us, the Company has incurred cash losses in the current financial year and in the immediately preceding financial year. Cash loss incurred for the current FY 2024-25 is Rs. 18.86 Crores & previous FY 2023-24 is Rs. 35.44 Crores
- xviii. There has been resignation of the statutory auditors by way of casual vacancy during the year. No issues, objections or concerns were raised by the outgoing auditors.
- xix. According to the information and explanations given to us and based on our examination of financial ratios, ageing and expected date of realization of financial assets and payment of liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans, we are of the opinion that no material uncertainty exists as on the date of audit report and the Company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.
- xx. According to the information and explanations given to us, the provisions of section 135 of the Act are not applicable to the Company. Hence, the provisions of paragraph (xx)(a) to (b) of the Order are not applicable to the Company.
- xxi. According to the information and explanations given to us, the Company does not have any subsidiary / Associate/ Joint Venture. So, there is no preparation of consolidated financial statements. Accordingly, the provisions stated in paragraph clause 3 (xxi) of the Order are not applicable to the Company.

**For B. Naga Bhushan & Co.,**  
Chartered Accountants  
Firm Registration No: 005584S

  
**B. Naga Bhushan**  
Partner

Membership No: 028574  
UDIN: 25028574BMJLJG9968



Place: Hyderabad  
Date: 10.05.2025



**B. NAGA BHUSHAN & Co.,**  
**CHARTERED ACCOUNTANTS**

Cell : 9849995678, 7382590368  
email : nagabhushanca@gmail.com  
bnagabhushan@yahoo.com  
1-1-380/38, Ashok Nagar Extn.,  
Hyderabad - 500 020. Telangana.

Date : 10.05.2025

**ANNEXURE B TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON  
THE FINANCIAL STATEMENTS OF CHALASANI HOSPITALS PRIVATE LIMITED**

[Referred to in paragraph 2(f) under 'Report on Other Legal and Regulatory Requirements' in the Independent Auditors' Report of even date to the Members of **CHALASANI HOSPITALS PRIVATE LIMITED** on the Financial Statements for the year ended March 31, 2025]

**Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of  
Section 143 of the Companies Act, 2013 ("the Act")**

We have audited the internal financial controls with reference to financial statements of **CHALASANI HOSPITALS PRIVATE LIMITED** ("the Company") as of March 31, 2025, in conjunction with our audit of the financial statements of the Company for the year ended on that date.

**Management's Responsibility for Internal Financial Controls**

The Company's Management is responsible for establishing and maintaining internal financial controls based on the internal control with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI) (the "Guidance Note"). These responsibilities include the design, implementation and maintenance of internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

**Auditors' Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether internal financial controls with reference to financial statements was established and maintained and if such controls operated effectively in all material respects.





**B. NAGA BHUSHAN & Co.,**  
**CHARTERED ACCOUNTANTS**

Cell : 9849995678, 7382590368  
email : nagabhushanca@gmail.com  
bnagabhushan@yahoo.com  
1-1-380/38, Ashok Nagar Extn.,  
Hyderabad - 500 020. Telangana.

Date : 10.05.2025

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

#### **Meaning of Internal Financial Controls With reference to Financial Statements**

A Company's internal financial control with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control with reference to financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.





**B. NAGA BHUSHAN & Co.,**  
**CHARTERED ACCOUNTANTS**

Cell : 9849995678, 7382590368  
email : nagabhushanca@gmail.com  
bnagabhushan@yahoo.com  
1-1-380/38, Ashok Nagar Extn.,  
Hyderabad - 500 020. Telangana.

Date : 10.05.2025

**Inherent Limitations of Internal Financial Controls With reference to financial statements**

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial control with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

**Opinion**

In our opinion, the Company has, in all material respects, internal financial controls with reference to financial statements and such internal financial controls with reference to financial statements were operating effectively as of March 31, 2025, based on the internal control with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note.

**For B. Naga Bhushan & Co.,**  
Chartered Accountants  
Firm Registration No: 005584S

  
B. Naga Bhushan  
Partner

Membership No: 028574  
UDIN: 25028574BMJLJG9968



Place: Hyderabad  
Date: 10.05.2025



**Chalasani Hospitals Private Limited**

CIN: U85110AP2010PTC068262

Balance sheet as at 31 March 2025

(All amounts are in millions of Indian Rupees except share data or unless otherwise stated)

	Note	As at 31 March 2025	As at 31 March 2024	As at 1 April 2023
<b>ASSETS</b>				
<b>Non-current assets</b>				
Property, plant and equipment	2.1 (a)	1,066	258	231
Capital work-in-progress	2.1 (b)	3	-	38
Intangible assets	2.1 (c)	2	3	-
Right to use-assets		83	-	-
Intangible Assets under Development		-	-	3
<b>Financial assets</b>				
(i) Investments	2.2	-	32	32
(i) Other financial assets	2.2(b)	40	44	40
Deferred tax assets (net)	2.31	131	-	16
Non-current tax assets (net)	2.7	31	41	73
Other non-current assets	2.3	92	31	41
<b>Total non-current assets</b>		<b>1,448</b>	<b>409</b>	<b>474</b>
<b>Current assets</b>				
Inventories	2.4	31	12	22
<b>Financial assets</b>				
(i) Trade receivables	2.5	218	173	476
(ii) Cash and cash equivalents	2.6 (a)	36	5	11
(iii) Other financial assets	2.2(c)	11	10	9
Other current assets	2.8	24	84	60
<b>Total current assets</b>		<b>320</b>	<b>284</b>	<b>578</b>
<b>Total assets</b>		<b>1,768</b>	<b>693</b>	<b>1,052</b>
<b>EQUITY AND LIABILITIES</b>				
<b>EQUITY</b>				
Equity share capital	2.9 (a)	53	53	52
Other equity	2.9 (b)	(416)	(318)	80
<b>Total equity</b>		<b>(363)</b>	<b>(265)</b>	<b>132</b>
<b>LIABILITIES</b>				
<b>Non-current liabilities</b>				
<b>Financial liabilities</b>				
(i) Borrowings	2.10	1,386	503	487
(iii) Lease Liability	2.24	79	-	-
Provisions	2.12	9	-	-
<b>Total non-current liabilities</b>		<b>1,474</b>	<b>503</b>	<b>487</b>
<b>Current liabilities</b>				
<b>Financial liabilities</b>				
(i) Borrowings	2.10	240	202	194
(ii) Trade payables	2.12	-	-	-
(a) Total outstanding dues of micro enterprises and small enterprises		-	-	-
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises		322	234	215
(iii) Other financial liabilities	2.11(b)	71	3	3
(iv) Lease Liability	2.24	4	-	-
Other current liabilities	2.15	10	16	21
Provisions	2.14	10	-	-
<b>Total current liabilities</b>		<b>657</b>	<b>455</b>	<b>433</b>
<b>Total liabilities</b>		<b>1,768</b>	<b>693</b>	<b>1,052</b>
<b>Material accounting policies</b>				
	1.3			

The accompanying notes referred to above form an integral part of the financial statements.

As per our report attached of even date.

for B.NAGA BHUSHAN & CO.,  
Chartered Accountants  
Firm Reg. No. 005584S

B.Naga Bhushan  
Partner  
Membership No. 028574  
UDIN: 25028574BMJLJG9968

Place: Hyderabad  
Date: 10.05.2025



for and on behalf of the Board of Directors of  
Chalasani Hospitals Private Limited

Nagendra B  
Parvathaneni  
Director  
DIN: 02025407

Place: Hyderabad  
Date: 10.05.2025

Veera Kishore  
Reddy Sane  
Director  
DIN: 03492323

Place: Hyderabad  
Date: 10.05.2025



**Chalasani Hospitals Private Limited**

**CIN: U85110AP2010PTC068262**

**Statement of Profit and loss for the period ended 31 March 2025**

(All amounts are in millions of Indian Rupees except share data or unless otherwise stated)

	Note	For the year ended 31 March 2025	For the year ended 31 March 2024
<b>Income</b>			
Revenue from operations	2.16	744	610
Other income	2.17	5	6
<b>Total Income</b>		<b>749</b>	<b>616</b>
<b>Expenses</b>			
Purchase of medical consumables, drugs and surgical instruments		162	142
(Increase)/Decrease in inventories of medical consumables, drugs and surgical instruments	2.18	(19)	10
Employee benefits expense	2.19	176	120
Finance costs	2.20	119	71
Depreciation and amortisation expense	2.21	42	30
Other expenses	2.22	498	630
<b>Total expenses</b>		<b>978</b>	<b>1,003</b>
<b>Loss before tax</b>		<b>(229)</b>	<b>(387)</b>
<b>Exceptional/ Extra-ordinary items</b>		<b>-</b>	<b>5</b>
<b>Loss Before Tax (VIII - IX)</b>		<b>(229)</b>	<b>(392)</b>
<b>Tax expense</b>			
- Current tax			-
- Deferred tax credit/(charge)		(131)	16
- Tax pertaining to previous years		-	14
<b>Total tax expense</b>		<b>(131)</b>	<b>30</b>
<b>Loss for the year</b>		<b>(98)</b>	<b>(422)</b>
<b>Other comprehensive income</b>			
<b>Items that will not be reclassified subsequently to profit and loss</b>			
- Re-measurement gain on defined benefit plans		-	-
- Income tax effect		-	-
<b>Other comprehensive income, net of tax</b>		<b>-</b>	<b>-</b>
<b>Total comprehensive loss for the year</b>		<b>(98)</b>	<b>(422)</b>

**Material accounting policies**

1.3

The accompanying notes referred to above form an integral part of the financial statements.

As per our report attached of even date.

**for B.NAGA BHUSHAN & CO.,**

Chartered Accountants

Firm Reg. No. 005584S

**B.Naga Bhushan**  
Partner

Membership No. 028574

UDIN: 25028574BMJLJG9968

Place: Hyderabad

Date: 10.05.2025



For and on behalf of the Board of Directors of  
**Chalasani Hospitals Private Limited**

**Nagendra B Parvataneni**  
Director  
DIN: 02025407

Place: Hyderabad  
Date: 10.05.2025

**Veera Kishore Reddy**  
Director  
DIN: 03492323

Place: Hyderabad  
Date: 10.05.2025



Chalasani Hospitals Private Limited  
CIN: U85110AP2010PTC068262  
Statement of Cash flows for the period ended 31 March 2025  
(All amounts are in millions of Indian Rupees except share data or unless otherwise stated)

	For the year ended 31 March 2025	For the year ended 31 March 2024
<b>I. Cash flows from operating activities:</b>		
Loss before tax	(229)	(387)
<b>Adjustments for operating activities:</b>		
Depreciation and amortisation expense	42	30
Loss on sale of property, plant and equipment	37	-
Provision of Expected credit loss for trade receivables (net of bad debts)	4	327
Trade receivables written off	-	4
Liabilities no longer required written back	116	-
Rental income	-	-
Interest income on fixed deposits and security deposits	(2)	(4)
Interest on income-tax refund	(2)	-
Finance costs	119	71
<b>Operating cash flows before working capital changes</b>	<b>85</b>	<b>41</b>
<b>Adjustments for:</b>		
Increase in trade receivables	(49)	(24)
Increase in inventories	(19)	10
Increase in loans and other assets	(61)	(26)
Increase in liabilities and provisions	99	15
<b>Cash generated from operations</b>	<b>55</b>	<b>16</b>
Income-taxes paid, net of refund	10	32
<b>Net cash flow generated from operating activities (A)</b>	<b>65</b>	<b>48</b>
<b>II. Cash flows from investing activities</b>		
Purchase of property, plant and equipment	(934)	(9)
Proceeds from sale of property, plant and equipment	-	-
Redemption of bank deposits (having original maturity of more than three months)	5	(3)
Investment in bank deposits (having original maturity of more than three months)	-	-
Rental income received	32	-
Sale of subsidiary investment	4	4
Interest received	-	-
<b>Net cash used in investing activities (B)</b>	<b>(893)</b>	<b>(8)</b>
<b>III. Cash flows from financing activities</b>		
Receipt from long-term borrowings	883	16
Repayment of long-term borrowings	-	-
Receipt from short-term borrowings	38	8
Payment of principal portion of lease liabilities	(1)	-
Payment of Interest on lease liabilities	(2)	-
Proceeds from Issue of Equity Shares	-	1
Finance Costs paid	(59)	(71)
<b>Net cash flows generated from financing activities (C)</b>	<b>859</b>	<b>(46)</b>
<b>Net increase in cash and cash equivalents (A+B+C)</b>	<b>31</b>	<b>(6)</b>
Cash and cash equivalents at the beginning of the year	5	11
<b>Cash and cash equivalents at the end of the period</b>	<b>36</b>	<b>5</b>

**Note:**

a) The statement of cash flows has been prepared under the "Indirect Method" as set out in the Indian accounting Standard (Ind AS 7)- Statement of cash flows:

b) Cash and cash equivalents comprises of:

	As at 31 March 2025	As at 31 March 2024
Cash on hand	1	1
Balances with banks		
- on current accounts	35	4
UDIN: 25028574BMJLJG9968	-	-
<b>Total</b>	<b>36</b>	<b>5</b>

The accompanying notes referred to above form an integral part of the financial statements.

As per our report attached of even date.

for **B.NAGA BHUSHAN & CO.,**  
Chartered Accountants  
Firm Reg. No. 005584S

*N. Naga Bhushan*  
B. Naga Bhushan  
Partner

Membership No. 028574  
UDIN: 25028574BMJLJG9968

Place: Hyderabad  
Date: 10.05.2025



for and on behalf of the Board of Directors of  
Chalasani Hospitals Private Limited

*Nagendra B Parvataneni*  
Nagendra B  
Parvataneni  
Director  
DIN: 02025407

*Veera Kishore Reddy*  
Veera Kishore Reddy  
Sane  
Director  
DIN: 03492323



Place: Hyderabad  
Date: 10.05.2025

Place: Hyderabad  
Date: 10.05.2025

**Chalasani Hospitals Private Limited**

CIN: U85110AP2010PTC068262

**Special Purpose Limited Review Statement of Changes in Equity for the period ended 31 March 2025**

(All amounts are in millions of Indian Rupees except share data or unless otherwise stated)

**a) Equity share capital**

Equity shares of Rs. 10 each issued, subscribed and fully paid

At 01 April 2023

Add: Shares issued during the year

At 31 March 2024

Add: Shares issued during the period

At 31 March 2025

Number of shares	Amount
49,69,510	50
2,04,798	2
51,74,308	52
-	-
51,74,308	52

**b) Other equity**

Particulars	Other equity		Total of Other equity
	Reserve and surplus		
	Securities premium	Retained earnings	
Balance as at 1 April 2023	80	0	80
Profit for the year	24	(422)	(398)
Re-measurement of defined benefit liability (net of tax)	-	-	-
Balance as at 31 March 2024	104	(422)	(318)
Profit for the period	-	(98)	(98)
Re-measurement of defined benefit liability (net of tax)	-	-	-
Balance as at 31 March 2025	104	(520)	(416)

The accompanying notes referred to above form an integral part of the financial statements.

As per our report attached of even date.

for **B.NAGA BHUSHAN & CO.,**

Chartered Accountants

Firm Reg. No. 005584S


**B.Naga Bhushan**  
Partner

Membership No. 028574

UDIN: 25028574BMJLJG9968

for and on behalf of the Board of Directors of  
**Chalasani Hospitals Private Limited**

**Nagendra B**  
**Parvataneni**  
Director

DIN: 02025407



**Veera Kishore Reddy**  
**Sane**  
Director

DIN: 03492323

Place: Hyderabad

Date: 10.05.2025

Place: Hyderabad

Date: 10.05.2025

Place: Hyderabad

Date: 10.05.2025



Chalasan Hospitals Private Limited  
CIN: U95110AP2010PTC068262

Notes to the financial statements for the period ended 31 March 2025  
(All amounts are in millions of Indian Rupees except share data or unless otherwise stated)

2.1 (a) Property, plant and equipment

Particulars	Freehold land	Buildings	Medical and surgical equipment	Plant and equipment	Office equipment	Electrical equipment	Computers	Furniture and fixtures	Vehicles	Total of Property, plant and equipment
Gross carrying amount										
Balance as at 1 April 2023	1	134	83	1	4	2	1	2	3	231
Additions	-	41	1	3	1	-	1	10	-	57
Disposals	-	-	-	-	-	-	-	-	-	-
Balance as at 31 March 2024	1	175	84	4	5	2	2	12	3	288
Balance as at 1 April 2024	1	175	84	4	5	2	2	12	3	288
Additions	359	476	29	10	1	2	5	0	0	882
Disposals	-	-	(38)	(1)	(3)	(1)	0	(12)	0	(55)
Balance as at 31 March 2025	360	651	75	13	3	3	7	-	3	1,115
Accumulated depreciation										
Balance as at 1 April 2023	-	-	-	-	-	-	-	-	-	-
Depreciation charge for the year	-	7	21	0	1	0	0	1	0	30
Disposals	-	-	-	-	-	-	-	-	-	-
Balance as at 31 March 2024	-	7	21	0	1	0	0	1	0	30
Balance as at 1 April 2024	-	7	21	-	1	-	-	1	-	30
Depreciation charge for the year	-	24	12	0	0	0	1	0	0	38
Disposals	-	-	(17)	0	(1)	0	0	(1)	-	(19)
Balance as at 31 March 2025	-	31	16	-	-	-	1	-	-	49

Carrying amounts (net)

At 1 April 2023	1	134	83	1	4	2	1	2	3	231
As at 31 March 2024	1	168	63	4	4	2	2	11	3	258
As at 31 March 2025	360	620	59	13	3	3	6	-	3	1,066

Note: "0" represents less than Rs.1 million.



Chalasani Hospitals Private Limited  
CIN: U85110AP2010PTC068262  
Notes to the financial statements for the period ended 31 March 2025  
(All amounts are in million of Indian Rupees, except share data or unless otherwise stated)

2.1(b) Capital Work in Progress

	As at 31 March 2025	As at 31 March 2024	As at 1 April 2023
Gross Carrying amount			
Balance as at	-	38	27
Additions	3	3	11
Capitalised during the period/year	-	(41)	-
Balance as at	3	-	38

i) For capital work in progress, aging Schedule as on 31 March 2025

CWIP	Amount in CWIP for a period of				Total
	< 1 year	1-2 years	2-3 years	more than 3 years	
-Projects in Progress	3	-	-	-	3
-Projects temporarily suspended	-	-	-	-	-
Total	3	-	-	-	3

ii) For capital work in progress, aging Schedule as on 31 March 2024

CWIP	Amount in CWIP for a period of				Total
	< 1 year	1-2 years	2-3 years	more than 3 years	
-Projects in Progress	3	11	27	-	41
-Projects temporarily suspended	-	-	-	-	-
Total	3	11	27	-	41

There are no capital work in progress projects, whose completion is overdue or has exceeded its cost compared to its original plan as at 31 March 2025 and 31 March 2024.

2.1 (c) Intangible assets

	Software
Balance as at 1 April 2023	0
Additions	3
Disposals	-
Balance as at 31 March 2024	3
Balance as at 1 April 2024	3
Additions	0
Disposals	0
Balance as at 31 March 2025	3
Accumulated amortization	
Balance as at 1 April 2023	-
Amortisation charge for the year	0
Disposals	-
Balance as at 31 March 2024	-
Balance as at 1 April 2024	-
Amortisation charge for the year	1
Disposals	0
Balance as at 31 March 2025	1
Carrying amounts (net)	
At 1 April 2023	-
As at 31 March 2024	3
As at 31 March 2025	2

Note: "0" represents less than Rs.1 million.



Chalasani Hospitals Private Limited

CIN: U85110AP2010PTC068262

Notes to the financial statements for the period ended 31 March 2025

(All amounts are in millions of Indian Rupees except share data or unless otherwise stated)

	As at 31 March 2025	As at 31 March 2024	As at 1 April 2023
<b>2.2 (a) Investments</b>			
Investment in subsidiaries - valued at cost			
i) Equity shares			
318,000 (31 March 2024: 318,000 ; 31 March 2023: 318,000) equity shares of Rs. 100 each fully paid up held in Vijaynagar Hospitals Private Limited	-	32	32
<b>Total</b>	<b>-</b>	<b>32</b>	<b>32</b>
Aggregate amount of unquoted investments	-	32	32
Aggregate provision for impairment in value of investments	-	-	-
<b>2.2 Other financial assets (at amortized cost)</b>			
(b) Non-current			
-To parties other than related parties			
(Unsecured, considered good)			
Bank deposits (due to mature after 12 months of reporting date)*	36	41	38
Security deposits	4	3	2
<b>Total</b>	<b>40</b>	<b>44</b>	<b>40</b>
* Includes Rs. 6 (31 March 2024: Rs. 11) deposits placed which are restrictive in nature as it pertains to bank guarantee. These guarantees are maturing after 12 months of the reporting date. And the for the amount of Rs.30 are kept under security lien for secured loan taken from Bandhan Bank.)			
(c) Current			
-To parties other than related parties			
(Unsecured, considered good)			
Contract assets	10	8	7
Security deposits	1	2	2
<b>Total</b>	<b>11</b>	<b>10</b>	<b>9</b>
<b>2.3 Other non-current assets</b>			
-To parties other than related parties			
(Unsecured, considered good)			
Capital advances	91	31	41
Balance with government authorities	1	-	-
<b>Total</b>	<b>92</b>	<b>31</b>	<b>41</b>
<b>2.4 Inventories</b>			
(Valued at lower of cost or net realizable value)			
Medical consumables, drug and surgical instruments	31	12	22
<b>Total</b>	<b>31</b>	<b>12</b>	<b>22</b>



2.5 Trade receivables (at amortized cost)  
(Unsecured)

Trade receivables - Considered good - Unsecured  
Trade receivables from related parties - Considered good - Unsecured (Refer note 2.28)  
Less: Allowance for expected credit loss

Trade receivables - credit impaired - Unsecured  
Less: Allowance for credit impairment  
Total

	As at 31 March 2025	As at 31 March 2024	As at 1 April 2023
Trade receivables - Considered good - Unsecured	549	500	476
Trade receivables from related parties - Considered good - Unsecured (Refer note 2.28)	-	-	-
Less: Allowance for expected credit loss	(331)	(327)	-
	218	173	476
Trade receivables - credit impaired - Unsecured	-	-	-
Less: Allowance for credit impairment	-	-	-
Total	218	173	476

No trade or other receivable are due from directors or other officers of the Company either severally or jointly with any other person, nor any trade or other receivable are due from firms or private companies respect director is a partner, a director or a member.

Trade receivables are non-interest bearing and generally on terms of 30 to 90 days.

Trade Receivables ageing schedule as on 31 March 2025

Particulars	Current but Not due	Outstanding for following periods from due date of payment					Total
		Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables-considered good	13	66	231	216	23	-	549
(ii) Undisputed Trade receivables- significant increase in credit risk	-	-	-	-	-	-	-
(iii) Undisputed Trade receivables-credit impaired	-	-	-	-	-	-	-
(iv) Disputed Trade receivables-considered good	-	-	-	-	-	-	-
(v) Disputed Trade receivables- significant increase in credit risk	-	-	-	-	-	-	-
(vi) Disputed Trade receivables-credit impaired	-	-	-	-	-	-	-
Total							549
Less: Allowance for expected credit loss							(331)
Balance at the end of the year							218

Trade Receivables ageing schedule as on 31 March 2024

Particulars	Current but Not due	Outstanding for following periods from due date of payment					Total
		Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables-considered good	8	167	4	127	87	107	500
(ii) Undisputed Trade receivables- significant increase in credit risk	-	-	-	-	-	-	-
(iii) Undisputed Trade receivables-credit impaired	-	-	-	-	-	-	-
(iv) Disputed Trade receivables-considered good	-	-	-	-	-	-	-
(v) Disputed Trade receivables- significant increase in credit risk	-	-	-	-	-	-	-
(vi) Disputed Trade receivables-credit impaired	-	-	-	-	-	-	-
Total							500
Less: Allowance for expected credit loss							(327)
Balance at the end of the year							173

Trade Receivables ageing schedule as on 1 April 2023

Particulars	Current but Not due	Outstanding for following periods from due date of payment					Total
		Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables-considered good	7	160	115	86	35	73	476
(ii) Undisputed Trade receivables- significant increase in credit risk	-	-	-	-	-	-	-
(iii) Undisputed Trade receivables-credit impaired	-	-	-	-	-	-	-
(iv) Disputed Trade receivables-considered good	-	-	-	-	-	-	-
(v) Disputed Trade receivables- significant increase in credit risk	-	-	-	-	-	-	-
(vi) Disputed Trade receivables-credit impaired	-	-	-	-	-	-	-
Total							476
Less: Allowance for expected credit loss							(476)
Balance at the end of the year							-







2.9(a) Equity share capital

Authorized  
Class A: 7,500,000 (31 March 2024: 7,500,000; 01 April 2023: 7,500,000) equity shares of INR 10 each  
Class B: 2,500,000 (31 March 2024: 2,500,000; 01 April 2023: 2,500,000) equity shares of INR 10 each  
Issued, subscribed and paid-up  
Class A: 4,969,510 (31 March 2024: 4,969,510; 01 April 2023: 4,969,510) equity shares of INR 10 each  
Class B: 264,977 (31 March 2024: 264,977; 01 April 2023: 204,798) equity shares of INR 10 each

	As at 31 March 2025	As at 31 March 2024	As at 1 April 2023
Authorized	75	75	75
Issued, subscribed and paid-up	25	25	25
	100	100	100
Class A	50	50	50
Class B	3	3	2
	53	53	52

a) Reconciliation of number of equity shares outstanding at the beginning and at the end of the year

Class A:	As at 31 March 2025		As at 31 March 2024	
Particulars	Number of shares	Amount	Number of shares	Amount
At the commencement of the year	49,69,510	50	49,69,510	50
Shares issued during the period/year	-	-	-	-
Shares outstanding at the end of the period/year	49,69,510	50	49,69,510	50
Class B:	As at 31 March 2025		As at 31 March 2024	
Particulars	Number of shares	Amount	Number of shares	Amount
At the commencement of the year	2,64,977	3	2,64,977	3
Shares issued during the period/year	-	-	-	-
Shares outstanding at the end of the period/year	2,64,977	3	2,64,977	3

b) Rights, preferences and restrictions attached to equity shares:

The Company has two class of equity shares having par value of Rs. 10 per share. Class A and Class B equity shares rank pari passu in respect of dividends and participation in surplus assets and profit in the event of winding up. However, Class B Equity Shares have voting rights only in respect of Reserved Matters whereas Class A Equity Shares have voting rights in respect of all the matters.

c) Particulars of shareholders holding more than 5% equity shares

Name of shareholder	As at 31 March 2025	% of holding	As at 31 March 2024	% of holding
Number of shares			Number of shares	
Krishna Institute of Medical Sciences Limited	52,34,477	100.00%	49,64,410	99.90%
Chalamsi Vijayalakshmi	-	0.00%	-	-

d) Shares held by holding company including shares held by subsidiaries or associates of the holding company

Name of shareholder	As at 31 March 2025	% of holding	As at 31 March 2024	% of holding
Number of shares			Number of shares	
Krishna Institute of Medical Sciences Limited	52,34,477	100.00%	49,64,410	99.90%
Vyas Cancer Research Private Limited	-	0.00%	89,666	33.84%
Biolam Inc.	-	0.00%	1,75,311	66.16%

e) The Company has not issued bonus shares during the period of five years immediately preceding the reporting period.

f) The Company has not bought back any shares during the period of five years immediately preceding the reporting period.

g) Details of shares held by Promoters

S. No.	Particulars	Promoter name	No of shares at beginning of the year	Change during the year	No of shares at end of the year	% of total shares	% change during the year
1	Equity shares of Rs. 10 each fully paid	Krishna Institute of Medical Sciences	-	52,34,477.00	52,34,477	100%	100%
2	Equity shares of Rs. 10 each fully paid	B Bhaskar Rao	-	10.00	10	0%	0%
3	Equity shares of Rs. 10 each fully paid	Chalamsi Vijayalakshmi	49,64,410	(49,64,410)	-	0%	-95%
4	Equity shares of Rs. 10 each fully paid	Vyas Cancer Research Private Limi	89,666	(89,666)	-	0%	-2%
5	Equity shares of Rs. 10 each fully paid	Biolam Inc.	1,75,311	(1,75,311.00)	-	0%	-3%
6	Equity shares of Rs. 10 each fully paid	Sairesh Chalamsi	2,550	(2,550.00)	-	0%	0%
7	Equity shares of Rs. 10 each fully paid	Usha Chalamsi	2,550	(2,550.00)	-	0%	0%
Total			52,34,487	-	52,34,487	100%	(0)
As at 31 March 2024							
S. No.	Particulars	Promoter name	No of shares at beginning of the year	Change during the year	No of shares at end of the year	% of total shares	% change during the year
1	Equity shares of Rs. 10 each fully paid	Chalamsi Vijayalakshmi	49,64,410	-	49,64,410	94.84%	0.00%
2	Equity shares of Rs. 10 each fully paid	Vyas Cancer Research Private Limi	89,666	-	89,666	1.71%	0.00%
3	Equity shares of Rs. 10 each fully paid	Biolam Inc.	1,15,132	60,179	1,75,311	3.35%	52.27%
4	Equity shares of Rs. 10 each fully paid	Sairesh Chalamsi	2,550	-	2,550	0.05%	0.00%
5	Equity shares of Rs. 10 each fully paid	Usha Chalamsi	2,550	-	2,550	0.05%	0.00%
Total			51,74,308	60,179	52,34,487	100.00%	0.52

2.9(b) Other equity

A) Retained earnings (refer note (i) below)

Opening balance  
Add: (Less) for the year  
Other comprehensive income:  
Remeasurement gains on defined benefit plans (net of tax)  
Closing balance (B)

B) Securities premium (Refer note (B) below)

Opening balance  
Add: Increase/(decrease) during the period/year  
Closing balance (C)

Total other equity (A+B)

	As at 31 March 2025	As at 31 March 2024	As at 1 April 2023
Opening balance	(422)	-	52
Add: (Less) for the year	(98)	(422)	(52)
Other comprehensive income:	-	-	-
Remeasurement gains on defined benefit plans (net of tax)	-	-	-
Closing balance (B)	(520)	(422)	-
Opening balance	104	80	-
Add: Increase/(decrease) during the period/year	-	24	80
Closing balance (C)	104	104	80
Total other equity (A+B)	(416)	(318)	80

Nature and purpose of reserves:

(i) Retained earnings

Retained earnings are the profits/losses (net of appropriation) of the company owned till date, including items of other comprehensive income.

(ii) Securities premium

Securities premium is used to record the premium received on issue of shares. It is utilized in accordance with the provisions of the Companies Act, 2013.



2.10 Current borrowings

(a) Non-current borrowings

Secured

Term loans from bank

-From Banks

i) Axis Bank 33085

ii) ICICI - 9291

iii) IDFC-4747

iv) IndusInd 0781

v) Yes Bank

vi) Bandhan Bank 20001

vi) Bandhan Bank 20002

vi) Bandhan Bank 10001

-From Financial Institutions

a) Fed - 1779

b) CREDIT 7485

c) Fulla 8369

d) Bajaj 2208

e) TATA 56026

f) U Gro 22300

Total loans from bank

Unsecured

Loans from related parties (refer note 2)

Total unsecured loans

Total

Secured

Working capital loan from bank (Refer note 1)

Current maturity of long term debts

Total

	As at 31 March 2025	As at 31 March 2024	As at 1 April 2023
<b>Secured</b>			
<b>Term loans from bank</b>			
-From Banks		402	487
i) Axis Bank 33085	2	-	-
ii) ICICI - 9291	1	-	-
iii) IDFC-4747	1	-	-
iv) IndusInd 0781	4	-	-
v) Yes Bank	2	-	-
vi) Bandhan Bank 20001	276	-	-
vi) Bandhan Bank 20002	-	-	-
vi) Bandhan Bank 10001	115	-	-
-From Financial Institutions		101	-
a) Fed - 1779	1	-	-
b) CREDIT 7485	-	-	-
c) Fulla 8369	1	-	-
d) Bajaj 2208	99	-	-
e) TATA 56026	-	-	-
f) U Gro 22300	1	-	-
<b>Total loans from bank</b>	<b>503</b>	<b>503</b>	<b>487</b>
<b>Unsecured</b>			
Loans from related parties (refer note 2)	883	-	-
<b>Total unsecured loans</b>	<b>883</b>	<b>-</b>	<b>-</b>
<b>Total</b>	<b>1,386</b>	<b>503</b>	<b>487</b>
<b>Secured</b>			
Working capital loan from bank (Refer note 1)	136	202	194
Current maturity of long term debts	104	-	-
<b>Total</b>	<b>240</b>	<b>202</b>	<b>194</b>

i) Axis Bank - Term loan Facility is secured by way of first charge on the medical equipment i.e. Phillips Preowned Ingenuity 128 Slice CT Scan. The loan is having a tenure of 60 months having 6 months of moratorium and carries an interest rate of Repo Rate + 4% i.e. 10.25% per annum (31 March 2024: 10.50% per annum).

ii) The Company has availed a Term Loan from ICICI Bank for purchase of Innova Cresta Vehicle which is repayable in 60 Equated Monthly installments commencing from April 2023. The loan is secured by way of Hypothecation of the vehicle purchased by availing the loan.

iii) The Company has availed a Term Loan from IDFC First Bank for which is repayable in 36 Equated Monthly installments commencing from November 2023 with a fixed interest rate of 10.99%. The loan is unsecured and is availed for the purpose of meeting working capital requirements.

iv) IndusInd Bank - Term loan Facility is secured by way of hypothecation of medical equipment. The loan is having a tenure of 30 months and carries an interest rate of floating rate linked to 6 months CD rate + spread 4.22% p.a. at monthly rest.

v) The Company has availed a Term Loan from Yes Bank for which is repayable in 60 Equated Monthly installments commencing from October 2023 with a fixed interest rate of 12%. The loan is unsecured and is availed for the purpose of meeting working capital requirements.

vi) Bandhan Bank - Term loan Facility is secured by way of exclusive charge by way of equitable mortgage of the hospital land & building (existing as well as proposed) & exclusive charge on movable fixed assets of the company both present & future and second charge over the current assets of the company & FD margin of Rs.3.0 Crs. The loan is having a tenure of 132 months having 12 months of moratorium and carries an interest rate of Repo Rate + 2% i.e. 8.25% per annum as on March 31st, 2025 and the repayment starts from January 2025 and end by February 2036.

a) FED Bank - Term Loan Facility is secured by secured by way of hypothecation of medical equipment. The loan is repayable in 37 equated monthly instalments starting November 2023 and carries an interest rate of 12.50% per annum (31 March 2024: 12.50% per annum).

b) The Company has availed a Term Loan from Credit Saison Finance India Pvt Ltd for which is repayable in 24 Equated Monthly installments commencing from December 2023 with a fixed interest rate of 17%. The loan is secured by way of Hypothecation of the medical equipment.

c) The Company has availed a Term Loan from SMFG India Credit Co Ltd for which is repayable in 37 Equated Monthly installments commencing from November 2023 with a fixed interest rate of 13.50%. The loan is unsecured and is availed for the purpose of meeting working capital requirements.

d) Bajaj Finance Facility is secured by collateral security as property H.No.19, S.No.336/P, House No.19, "BAY MOUNT" Project, Layout No. 103/89, Rushikonda Layout, Tarakarama Nagar, Madhurawada, GVMC Limits, Visakhapatnam, Andhra Pradesh. The loan is repayable in 180 equated monthly instalments starting November 2023 and carries an interest rate of Repo rate + 3% i.e. 9.25% per annum (31 March 2024: 9.50% per annum)

e) TATA Capital - Unsecured business loan Facility is having a tenure of 24 months (Oct 23 to Oct 25) and carries an interest rate of 13.50% p.a.

f) UGRO Capital - Unsecured business loan Facility is having a tenure of 36 months (Dec 23 to Nov 26) and carries an interest rate of 17.50% p.a.

1. Working capital loan from Bandhan bank is secured by exclusive charge over entire current assets of the company both present & future including stocks, receivables and all other current assets and second charge on hospital land & building, other movable assets of the Company. Loan is repayable on demand and carries an interest rate of Repo rate + 2.00% per annum (31 March 2025: 6.25% per annum).

2. Unsecured loan from related parties as at 31 March, 2025 represented loans obtained from Krishna Institute of Medical Sciences Limited (Holding Company) and carrying interest rate of 12% p.a. (refer note 2.25).



2.11 Other financial liabilities (at amortized cost)

(a) Current

Capital creditors  
Employee benefits payable \*  
Interest accrued but not due

Total

\*Includes payables to related parties such as Krishna Institute of Medical sciences Limited and Rajyalaxmi Hospitals Private Limited

As at 31 March 2025	As at 31 March 2024	As at 1 April 2023
12	-	-
1	-	-
58	3	3
71	3	3

2.12 Non- Current provisions

Provision for employee benefits

Gratuity

Total

9	-	-
9	-	-

2.13 Trade payables (at amortized cost)

Trade payables

- total outstanding dues of micro enterprises and small enterprises

- total outstanding dues of creditors other than micro enterprises and small enterprises

Total

The above includes payable to related parties.

Trade payables are non-interest bearing and are normally settled on 30-90 day terms.

-	-	-
322	234	215
322	234	215

Trade Payable Ageing Schedule as on 31 March 2025

Particulars	Unbilled dues	Outstanding for following periods from due date of payment				Total
		< 1 year	1-2 years	2-3 years	More than 3 years	
(i) Total outstanding dues of micro enterprises and small enterprises	-	-	-	-	-	-
(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	20	186	107	9	-	322
(iii) Disputed dues of micro enterprises and small enterprises	-	-	-	-	-	-
(iv) Disputed dues of creditors other than micro enterprises and small enterprises	-	-	-	-	-	-
Total						322

Trade Payable Ageing Schedule as on 31 March 2024

Particulars	Unbilled dues	Outstanding for following periods from due date of payment				Total
		< 1 year	1-2 years	2-3 years	More than 3 years	
(i) Total outstanding dues of micro enterprises and small enterprises	-	-	-	-	-	-
(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	2	180	41	4	7	234
(iii) Disputed dues of micro enterprises and small enterprises	-	-	-	-	-	-
(iv) Disputed dues of creditors other than micro enterprises and small enterprises	-	-	-	-	-	-
Total						234

Trade Payable Ageing Schedule as on 01 April 2023

Particulars	Unbilled dues	Outstanding for following periods from due date of payment				Total
		< 1 year	1-2 years	2-3 years	More than 3 years	
(i) Total outstanding dues of micro enterprises and small enterprises	-	-	-	-	-	-
(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	2	174	30	4	5	215
(iii) Disputed dues of micro enterprises and small enterprises	-	-	-	-	-	-
(iv) Disputed dues of creditors other than micro enterprises and small enterprises	-	-	-	-	-	-
Total						215

2.14 Current provisions

Provision for employee benefits

Gratuity

Compensated absences

Total

6	-	-
4	-	-
10	-	-

2.15 Other liabilities

(a) Current

Statutory dues payable

Contract liabilities

Total

8	15	20
2	1	1
10	16	21





**Chalasani Hospitals Private Limited****CIN: U85110AP2010PTC068262****Notes to the financial statements for the period ended 31 March 2025**

(All amounts are in millions of Indian Rupees except share data or unless otherwise stated)

	For the year ended 31 March 2025	For the year ended 31 March 2024
<b>2.16 Revenue from operations</b>		
<b>A Revenue from medical and healthcare services (Refer note 2.32)</b>		
Income from hospital services	533	473
Income from sale of pharmacy and others	210	137
<b>Total</b>	<b>743</b>	<b>610</b>
<b>B Other operating income</b>		
Income from other operation	1	-
<b>Total</b>	<b>1</b>	<b>-</b>
<b>Total Revenue from operations</b>	<b>744</b>	<b>610</b>
<b>2.17 Other income</b>		
Interest on:		
- fixed deposits	2	4
- income-tax refunds	2	-
Miscellaneous income	1	2
<b>Total</b>	<b>5</b>	<b>6</b>



**Chalasani Hospitals Private Limited**

**CIN: U85110AP2010PTC068262**

**Notes to the financial statements for the period ended 31 March 2025**

(All amounts are in millions of Indian Rupees except share data or unless otherwise stated)

	For the year ended 31 March 2025	For the year ended 31 March 2024
<b>2.18 (Increase)/Decrease in inventories of medical consumables, drugs and surgical instruments</b>		
Opening stock	12	22
Less: Closing stock	31	12
<b>Total</b>	<b>(19)</b>	<b>10</b>
<b>2.19 Employee benefits expense</b>		
Salaries, wages and bonus	155	116
Contribution to provident and other funds	21	3
Staff welfare expenses	-	1
<b>Total</b>	<b>176</b>	<b>120</b>
<b>2.20 Finance costs</b>		
Interest expense on		
- term loans	55	68
- Lease Liability	2	-
- Loan from related parties	62	-
Others	-	3
<b>Total</b>	<b>119</b>	<b>71</b>
<b>2.21 Depreciation and amortisation expense</b>		
Depreciation of property, plant and equipment (refer note no 2.1(a))	38	30
Amortisation on ROU assets	3	-
Amortisation of intangible assets (refer note no 2.1(c))	1	-
<b>Total</b>	<b>42</b>	<b>30</b>
<b>2.22 Other expenses</b>		
Consultancy charges	208	166
House keeping expenses	35	23
Power and fuel	20	19
Catering and patient welfare expenses	6	5
Rent	5	4
Repairs and maintenance:		
- Medical equipment	28	21
- Hospital building and others	11	23
Printing and stationery	3	3
Audit fee	1	1
Legal and professional charges	5	12
Rates and taxes	3	3
Traveling and conveyance	3	1
Advertisement and publicity	3	4
Expected credit loss for trade receivables	4	327
Advance written off	153	4
Insurance	1	1
Bank charges	4	3
Miscellaneous expenses	5	10
<b>Total</b>	<b>498</b>	<b>630</b>

**Note A: Payment to auditors (excluding applicable taxes)**

Particulars	For the year ended 31 March 2025	For the year ended 31 March 2024
Audit fee	1	1
Out of pocket expenses	-	0



Chalasani Hospitals Private Limited

CIN: U85110AP2010PTC068262

Notes to the financial statements for the period ended 31 March 2025

(All amounts are in millions of Indian Rupees except share data or unless otherwise stated)

## 2.23 Contingent liabilities and commitments

(a) Includes a consumer case filed by an individual at National Consumer Disputes Redressal Commission against the Company demanding a total compensation of Rs. 1Mn (31 March 2024: Rs. 1 Mn) towards medical negligence. Based on the legal opinion obtained by the Company and the internal evaluation by the management, the Company believes that it has strong case in this regard and there shall not be any outflow of resources. No provision thereof has been made in the financial statements.

### b) Commitments

Particulars	As at	As at
	31 March 2025	31 March 2024
Estimated amount of contracts remaining to be executed on capital account and not provided for (net of advances)	377	42



**2.24 Lease****Operating and Finance leases in the capacity of lessee.**

The Company has lease contracts for buildings used in its operations with lease terms between 3 and 10 years. The Company's obligations under its leases are secured by the lessor's title to the leased assets.

The Company has lease contract that include extension and termination options. These options are negotiated by management to provide flexibility in managing the leased-asset portfolio and align with the Company's business needs. Management exercises significant judgement in determining whether these extension and termination options are reasonably certain to be exercised.

Set out below are the carrying amounts of right-of-use assets recognised and the movements during the year:

Particulars	Leasehold Building	Total
As at 1 April 2023	-	-
Addition on adoption of Ind AS 116	-	-
Additions	-	-
Amortization expense	-	-
As at 31 March 2024	86	86
Additions	-	-
Amortization expense	3	3
As at 31 March 2025	83	83

Set out below are the carrying amounts of lease liabilities and the movements during the year:

	As at 31 March 2025	As at 31 March 2024
Opening balance	-	-
Additions	84	-
Accretion of interest	2	-
Payments	(3)	-
As at 31 March	83	-
Current	4	-
Non-current	79	-

The following are the amounts recognised in profit or loss:

	As at 31 March 2025	As at 31 March 2024
Amortization expense of right-of-use assets	3	-
Interest expense on lease liabilities	2	-
Expense relating to short-term leases and low-value assets (included in other expenses)	5	-
Total amount recognised in profit or loss	10	-

The Company had total cash outflows for leases of Rs. 8 in 31 March 2025 (31 March 2024: Rs. 0).

The table below provides details regarding the undiscounted contractual maturities of lease liabilities:

	As at 31 March 2025	As at 31 March 2024
Within less than one year	11	-
Between one and five years	49	-
After more than five years	68	-
Total	128	-



**2.25 Employee benefits****Defined benefit plan**

The Company operates post employment defined benefit plan that provides for gratuity. The gratuity plan entitles an employee, who has rendered at least five years of continuous services, to receive one-half month's salary for each year of completed services at the time of retirement/exit. The gratuity fund is administered by trust formed for this purpose and is managed by Life Insurance Corporation of India. The Company's obligation in respect of gratuity plan, which is a defined benefit plan is provided for based on actuarial valuation carried out by an independent actuary using the projected unit credit method. The Company accrues gratuity as per the provisions of the Payment of Gratuity Act, 1972 as applicable as at the balance sheet date.

**A Based on the actuarial valuation obtained in this respect, the following table sets out the status of the gratuity plan and the amounts recognized in the Company's financial statements as at the balance sheet date:**

Particulars	As at 31 March 2025	As at 31 March 2024
Present value of defined benefit obligation	15	-
Fair value of plan assets	-	-
Net present value of defined benefit obligation	15	-
Non-current	9	-
Current	6	-

**B Reconciliation of net defined benefit obligation**

The following table shows a reconciliation from the opening balances to the closing balances for net defined benefit obligation and its components.

**i) Reconciliation of present value of defined benefit obligation**

Particulars	As at 31 March 2025	As at 31 March 2024
Defined benefit obligation as at 1 April	-	-
Current service cost	15	-
Interest cost on defined net benefit plan	1	-
Actuarial (gains) / losses recognized in other comprehensive income	-	-
- changes in financial assumptions	-	-
- experience adjustments	-	-
Benefits paid	-	-
Defined benefit obligation as at 31 March	15	-

**C i) Expenses recognized in statement of profit and loss**

Particulars	For the year ended 31 March 2025	For the year ended 31 March 2024
Current service cost	15	-
Interest on defined benefit obligation / plan assets (net)	1	-
Net gratuity cost, included in 'employee benefits'	16	-

**C ii) Re-measurements recognized in other comprehensive income**

Particulars	For the year ended 31 March 2025	For the year ended 31 March 2024
Actuarial (gain) / loss on defined benefit obligation	-	-





**D Defined benefit obligation****i) Actuarial assumptions**

Principal actuarial assumptions	As at	As at
	31 March 2025	31 March 2024
Discount rate	6.55%	7.15%
Salary escalation rate	8.00%	8.00%

**Maturity profile of defined benefit obligation**

Particulars	As at	As at
	31 March 2025	31 March 2024
1st following year	6	-
2 to 5 years	10	-
Year 6 to 9	2	-
10 years and above	-	-

Discount rate: The discount rate is based on the prevailing market yields of Indian government securities as at the balance sheet date for the estimated term of the obligations.

Salary escalation rate: The estimates of future salary increases considered takes into accounts the inflation, seniority, promotion and other relevant factors.

Expected rate of return on plan assets: This is based on the expectation of the average long term rate of return expected on investment of the fund during the estimated term of the obligations.

**ii) Sensitivity analysis**

Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions would have affected the defined benefit obligation by the amounts shown below:

Particulars	For the year ended 31 March 2025		For the year ended 31 March 2024	
	Increase	Decrease	Increase	Decrease
Discount rate (0.5% movement)	-	1	-	-
Salary escalation rate (0.5% movement)	1	-	-	-

Although the analysis does not take account of the full distribution of the cash flows expected under the plan, it does provide an approximation of the sensitivity of the assumption shown.

**E Defined contribution plan**

Particulars	For the year ended	For the year ended
	31 March 2025	31 March 2024
Amount recognized in the statement of profit and loss towards		
i) Provident fund	2	2

- (iii) The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.



Chalasani Hospitals Private Limited  
CIN: U85110AP2010PTC068262  
Notes to the financial statements for the period ended 31 March 2025  
(All amounts are in millions of Indian Rupees except share data or unless otherwise stated)

2.26 Related party disclosures

(a) Parties where control exists or where significant influence exists and with whom transactions have taken place during the current year or previous year:

Nature of relationship	Name of related parties
Holding Company	Krishna Institute of Medical Sciences Limited
Key Managerial Personnel (KMP)	Ms. Vijaya Lakshmi Chalasani Mr. Saileesh Chalasani Mr. Nagendra B Parvataneni (Additional Directors) (w.e.f 31.08.2025) Mr. Sana Kishore Kumar Reddy (Additional Directors) (w.e.f 31.08.2025)
Relative to KMP	Ms. Usha Chalasani
Fellow Subsidiaries	KIMS Hospitals Enterprises Private Limited Rajyalakshmi Hospitals Private Limited KIMS Swastha Private Limited
Enterprises in which Key Management Personnel and / or their Relatives have significant influence	Chalasani Bio-Pharma Pvt Ltd. Vijayanagar Hospitals Pvt Ltd.

(b) Transaction with related parties

Particulars	For the year ended 31 March 2025	For the year ended 31 March 2024
Saileesh Chalasani Professional Charges	-	5
Usha Chalasani Professional Charges	-	2
Chalasani Bio-Pharma Pvt.Ltd. Purchase of Medicines	-	2
KIMS Swastha Private Limited Advances given	5	-
Rajyalakshmi Hospitals Private Limited Loans & Advances taken Interest Expense	70 1	-
KIMS Hospitals Enterprises Private Limited Advances taken	25	-
Krishna Institute of Medical Sciences Limited Purchase of medical consumables, drugs and surgical instruments Loans & Advances taken Interest Expense Advances taken	1 868 61 40	- - - -

(c) The balances payable to related parties

Particulars	As at 31 March 2025	As at 31 March 2024
i. Krishna Institute of Medical Sciences Limited Trade Payable Advances taken Unsecured Loans Interest Payable	1 40 868 54	- - - -
ii. KIMS Hospitals Enterprises Private Limited Advances taken	25	-
iii. Rajyalakshmi Hospitals Private Limited Unsecured Loans Interest Payable	15 0	- -
iv. Vijaya Lakshmi Chalasani Capital Advances Advances Recoverable in Cash or Kind	- -	31 54
v. Saileesh Chalasani Professional Charges Payable	-	11
vi. Usha Chalasani Trade Payables	-	4
vii. Vijayanagar Hospitals Pvt Ltd. Investment Advances Recoverable in Cash or Kind	- -	32 1
viii. Chalasani Bio-Pharma Pvt Ltd Advances Recoverable in Cash or Kind	-	6

Note: "0" represents less than Rs.1 million.

Terms and conditions:

All transactions with these related parties are priced on arm's length basis and resulting outstanding receivables and payables including financial assets and financial liabilities balances are settled in cash within a range of 30-120 days of the transaction date. None of the balances are secured.



Chalasani Hospitals Private Limited

CIN: U85110AP2010PTC068262

Notes to the financial statements for the period ended 31 March 2025

(All amounts are in millions of Indian Rupees except share data or unless otherwise stated)

**2.27 Earnings per share (EPS)**

Basic EPS amounts are calculated by dividing the profit for the year attributable to equity shareholders of the Company by the weighted average number of Equity shares outstanding during the year. The weighted average number of equity shares outstanding during the period is adjusted for share split that have changed the number of equity shares outstanding, without a corresponding change in reserves.

Diluted EPS amounts are calculated by dividing the profit attributable to owners of the company by the weighted average number of Equity shares outstanding during the year plus the weighted average number of Equity shares that would be issued on conversion of all the dilutive potential Equity shares into Equity shares. The weighted average number of equity shares including dilutive potential equity shares, outstanding during the period is adjusted for share split that have changed the number of equity shares outstanding, without a corresponding change in reserves.

Particulars	For the year ended 31 March 2025	For the year ended 31 March 2024
<b>Earnings</b>		
Loss for the year attributable to equity shareholders	(98)	(422)
<b>Shares</b>		
Number shares at the beginning of the year	52,34,487	52,34,487
Add: Equity shares issued during the year	-	-
Total number of equity shares outstanding at the end of the year	52,34,487	52,34,487
Weighted average number of equity shares outstanding during the year - Basic and Diluted	52,34,487	52,34,487
Earnings per share of par value Rs. 10 each - Basic and Diluted (Rs.)	(19)	(81)

There are no potentially dilutive equity shares and therefore basic and diluted EPS are the same.



Chalasani Hospitals Private Limited

CIN: U85110AP2010PTC068262

Notes to the financial statements for the period ended 31 March 2025

(All amounts are in millions of Indian Rupees except share data or unless otherwise stated)

## 2.28 Segment information

The Board of Directors of the Company takes decision in respect of allocation of resources and assesses the performance basis the report/ information provided by functional heads and are thus considered to be Chief Operating Decision Maker.

Based on the Company's business model, Medical and Healthcare services have been considered as a single business segment for the purpose of making decision on allocation of resources and assessing its performance. Accordingly, there are no separate reportable segments in accordance with the requirements of Ind AS 108 'Operating segment' and hence, there are no additional disclosures to be provided other than those already provided in the consolidated financial statements. Presently, the Company's operations are predominantly confined in India. There are no individual customer contributing more than 10% of Company's total revenue. All non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets of the Company are located in India.

## 2.29 Due to Micro and Small Enterprises

The Ministry of Micro, Small and Medium Enterprises has issued an office memorandum dated 26 August 2008 which recommends that the Micro and Small Enterprises should mention in their correspondence with its customers the Entrepreneurs Memorandum Number as allocated after filing of the Memorandum. Accordingly, the disclosure in respect of the amount payable to such enterprises as at 31 March 2025 has been made in the financial statements based on information received and available with the Company. Further in view of the Management, the impact of interest, if any, that may be payable in accordance with the provisions of the Micro, Small and Medium Enterprises Development Act, 2006 (The MSMED Act) is not expected to be material. The Company has not received any claim for interest from any supplier.

Particulars	As at 31 March 2025	As at 31 March 2024
The amounts remaining unpaid to micro and small supplies as at end of the year		
- Principal	-	-
- Interest	-	-
The amount of interest paid by the buyer in terms of Section 16 of the Micro, Small and Medium Enterprises Development Act, 2006 (27 of 2006), along with the amount of the payment made to the supplier beyond the appointed day during each accounting year;	-	-
The amount of interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act;	-	-
The amount of interest accrued and remaining unpaid at the end of each accounting year; and	-	-
The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprises for the purpose of disallowance as a deductible expenditure under Section 23 of the MSMED Act.	-	-



Chalasani Hospitals Private Limited

CIN: U85110AP2010PTC068262

Notes to the financial statements for the period ended 31 March 2025

(All amounts are in millions of Indian Rupees except share data or unless otherwise stated)

### 2.30 Capital management

The Company's policy is to maintain a stable capital base so as to maintain investor and creditor confidence and to sustain future development of the business. Management monitors capital on the basis of return on capital employed as well as the 'net debt' to 'total equity' ratio.

For this purpose, net debt is defined as total borrowings, less cash and cash equivalents. Total equity comprises of issued share capital and all other equity reserves.

The Company's net debt to equity ratio as of 31 March 2025 and 31 March 2024 was as follows:

Particulars	As at 31 March 2025	As at 31 March 2024	As at 01 April 2023
Total borrowings	1,626	705	681
Less: Cash and cash equivalents	36	5	11
Net debt	1,590	700	670
Total equity	(363)	(265)	132
Net debt to equity ratio	-400%	-300%	500%

In order to achieve this overall objective, the Company's capital management, amongst other things, aims to ensure that it meets financial covenants attached to the interest-bearing loans and borrowings that define capital structure requirements. Breaches in meeting the financial covenants would permit the bank to immediately call loans and borrowings. There have been no breaches in the financial covenants of any interest-bearing loans and borrowing in the current year.

No changes were made in the objectives, policies or processes for managing capital during the year ended 31 March 2025 and 31 March 2024.





2.31 Financial instruments : Fair value and risk management

A. Accounting classification and fair values

The management assessed that loans, trade receivables, cash and cash equivalents, other financial assets, borrowings, trade payables and other financial liabilities approximate their carrying amounts as fair value.

As at 31 March 2025	Carrying Value	Fair Value	Fair value level
<b>Financial assets at amortised cost (Refer note below)</b>			
Trade receivables	218	218	
Cash and cash equivalents	36	36	
Other financial assets	51	51	
<b>Total</b>	<b>305</b>	<b>305</b>	
<b>Financial liabilities at amortised cost (Refer note below)</b>			
Long-term borrowings	1,386	1,386	
Current borrowings	240	240	
Lease liabilities	83	83	
Trade payables	322	322	
Other financial liabilities	71	71	
<b>Total</b>	<b>2,102</b>	<b>2,102</b>	level 3

As at 31 March 2024	Carrying Value	Fair Value	Fair value level
<b>Financial assets at amortised cost (Refer note below)</b>			
Trade receivables	173	173	
Cash and cash equivalents	5	5	
Bank balances other than above	-	-	
Other financial assets	54	54	
<b>Total</b>	<b>232</b>	<b>232</b>	
<b>Financial liabilities at amortised cost (Refer note below)</b>			
Loan-term borrowings	503	503	
Short-term borrowings	202	202	
Lease liabilities	-	-	
Trade payables	234	234	
Other financial liabilities	3	3	
<b>Total</b>	<b>439</b>	<b>439</b>	level 3

Note for financial assets and financial liabilities at amortised cost:

The carrying amounts of trade receivables, trade payables, other financial assets, other financial liabilities and cash and cash equivalents and bank balances other than cash and cash equivalents are considered to be the same as their fair values, due to their short-term nature.

The fair values of lease liability are based on discounted cash flows using a current borrowing rate. They are classified as level 3 fair value hierarchy due to the use of unobservable inputs including own credit risk.

The fair value of loans were calculated based on discounted cashflows using current lending rate. They are classified as level 3 fair values hierarchy due to the inclusion of observable inputs including counter party credit risk.



**2.31 Financial instruments : Fair value and risk management (continued)**

**B. Financial risk management**

The Company's activities expose it to a variety of financial risks: credit risk, market risk and liquidity risk.

**(i) Risk management framework**

The Company's Board of Directors has overall responsibility for the establishment and oversight of the Company's risk management framework. The Company's risk management policies are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities.

The Company's board of directors oversees how management monitors compliance with the Company's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Company.

**(ii) Credit risk**

Credit risk is the risk that the counterparty will not meet its obligation under a financial instrument or customer contract, leading to financial loss. The credit risk arises principally from its operating activities (primarily trade receivables) and from its investing activities, including deposits with banks and financial institutions and other financial instruments. The carrying amounts of financial assets represent the maximum credit risk exposure.

Credit risk is controlled by analysing credit limits and creditworthiness of customers on a continuous basis to whom credit has been granted after obtaining necessary approvals for credit. The collection from the trade receivables are monitored on a continuous basis by the receivables team.

The Company establishes an allowance for credit loss that represents its estimate of expected losses in respect of trade and other receivables based on the past and the recent collection trend. The maximum exposure to credit risk as at reporting date is primarily from trade receivables amounting to Rs. 549 as on 31 March 2025 (31 March 2024 : Rs.500 ; 01 April 2023 : Rs.476). The movement in allowance for credit loss in respect of trade and other receivables during the year was as follows:

	As at 31 March 2025	As at 31 March 2024
Allowance for credit losses		
Opening balance	327	-
Credit loss added/ reversed	4	327
Closing balance	331	327

Trade receivable write off not routed through the above movement

The Company uses a provision matrix to determine the expected credit loss on the portfolio of its trade receivables and contract assets. The provision matrix is based on its historically observed default rates over the expected life of the trade receivables and contract assets and is adjusted for forward looking estimates. The expected credit loss allowance is based on the ageing of the days the receivables are due in the provision matrix. Set out below is the information about the credit risk exposure of the Company's trade receivables and contract asset using provision matrix:

	Not past due	0-180 days due past due date	More than 180 days past due date	Gross trade receivables and contract assets
For the year ended 31 March 2025	23	66	470	559
For the year ended 31 March 2024	16	167	325	508
For the year ended 01 April 2023	14	160	309	483

**Customer Concentration**

No single customer represents 10% or more of the company's total revenue during the year ended 31 March 2025 and year ended 31 March 2024. Therefore the customer concentration risk is limited due to the large and unrelated customer base.

Credit risk on cash and cash equivalent is limited as the company generally transacts with banks and financial institutions with high credit ratings assigned by international and domestic credit rating agencies.



**(iii) Liquidity risk**

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company has an established liquidity risk management framework for managing its short term, medium term and long term funding and liquidity management requirements. The Company's exposure to liquidity risk arises primarily from mismatches of the maturities of financial assets and liabilities. The Company manages the liquidity risk by maintaining adequate funds in cash and cash equivalents. The Company also has adequate credit facilities agreed with banks to ensure that there is sufficient cash to meet all its normal operating commitments in a timely and cost-effective manner.

The table below provides details regarding the undiscounted contractual maturities of significant financial liabilities as of 31 March 2025

Particulars	Carrying value	Less than 1 year	1 - 5 years	More than 5 years	Total
Long-term borrowings (excluding current maturities)	1,386	-	1,276	110	1,386
Short-term borrowings	240	240	-	-	240
Trade payables	322	322	-	-	322
Lease liabilities	83	4	24	55	83
Other financial liabilities	71	12	59	-	71
<b>Total</b>	<b>2,102</b>	<b>578</b>	<b>1,359</b>	<b>165</b>	<b>2,102</b>

The table below provides details regarding the undiscounted contractual maturities of significant financial liabilities as of 31 March 2024

Particulars	Carrying value	Less than 1 year	1 - 5 years	More than 5 years	Total
Long-term borrowings (excluding current maturities)	503	-	487	16	503
Short-term borrowings	202	202	-	-	202
Trade payables	234	234	-	-	234
Lease liabilities	-	-	-	-	-
Other financial liabilities	3	3	-	-	3
<b>Total</b>	<b>439</b>	<b>439</b>	<b>487</b>	<b>16</b>	<b>942</b>

The table below provides details regarding the undiscounted contractual maturities of significant financial liabilities as of 1 April 2023

Particulars	Carrying value	Less than 1 year	1 - 5 years	More than 5 years	Total
Long-term borrowings (excluding current maturities)	487	-	487	-	487
Short-term borrowings	194	194	-	-	194
Trade payables	215	215	-	-	215
Lease liabilities	-	-	-	-	-
Other financial liabilities	3	3	-	-	3
<b>Total</b>	<b>412</b>	<b>412</b>	<b>487</b>	<b>-</b>	<b>899</b>

**(iv) Market risk****(a) Interest rate risk exposure**

The exposure of the Company's borrowing to interest rate changes at the end of the reporting period are as follows:

Particulars	As at 31 March 2025	As at 31 March 2024	As at 30 April 2023
Variable rate long term borrowings including current maturities and short term borrowings	743	705	681
<b>Total borrowings</b>	<b>743</b>	<b>705</b>	<b>681</b>

**(b) Cash flow sensitivity analysis**

Particulars	Impact on profit or loss		Equity, net of tax	
	For the year ended 31 March 2025	For the year ended 31 March 2024	For the year ended 31 March 2025	For the year ended 31 March 2024
<b>Sensitivity</b>				
1% increase in MCLR	7	(7)	7	(7)
1% decrease in MCLR	(7)	7	(7)	7

The interest rate sensitivity is based on the closing balance of secured term loans and working capital loan from banks.

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: interest rate risk, currency risk and other price risk, such as equity price risk and commodity risk. The Company does not have any financial instruments which are affected by market risk.

**(v) Currency risk**

The Company is not exposed to currency risk.



2.32 Income tax

a. Amount recognised in statement of profit and loss	For the year ended 31 March 2025	For the year ended 31 March 2024
Current year tax	-	-
Deferred tax attributable to temporary differences	(131)	16
Tax expenses for the year	(131)	16

b. Amount recognised in other comprehensive income	For the year ended 31 March 2025			For the year ended 31 March 2024		
	Before tax	Tax (expense)/ benefit	Net of tax	Before tax	Tax (expense)/ benefit	Net of tax
Re-measurement on defined benefit plans	-	0	-	-	-	-

c. Reconciliation of effective tax rate	For the year ended 31 March 2025	For the year ended 31 March 2024
Profit/ (loss) before tax	(129)	(387)
Enacted tax rates	0	0
Tax expense at enacted rates	(58)	(97)
Tax effect of amounts which are not deductible/ (taxable) in calculating taxable income		
Non-deductible expenses	48	-
Deferred tax not recognised on various items (net)	10	97
	-	-

d. Recognition of deferred tax assets and liabilities

(i) Deferred tax assets and liabilities are attributable to the following

Particulars	As at 31 March 2025	As at 31 March 2024
Deferred tax asset	(5)	-
Provision for employee benefits	(46)	-
On Losses	(51)	-
Total deferred tax asset		
Deferred tax Liability	5	-
Property, plant and equipment	(83)	-
Provision for doubtful receivables	0	-
Finance Lease	(78)	-
Total deferred tax liability	(129)	-
Deferred tax liability/asset (net)		

\*Tax loss, unabsorbed depreciation carry-forward and others for which no deferred tax assets were recorded amounting to Rs. Nil (31 March 2024: Rs. Nil)

(ii) Movement in temporary differences

Particulars	Provision for doubtful receivables	Provision for employee benefits	Others	Property, plant and equipment	Total
Balance as at 1 April 2023	-	-	-	-	-
Recognised in profit or loss during 2023-24	-	-	-	-	-
Recognised in OCI during 2023-24	-	-	-	-	-
Balance as at 31 March 2024	-	-	-	-	-
Recognised in profit or loss during 2024-25	(83)	(5)	(46)	5	(129)
Recognised in OCI during 2024-25	-	-	-	-	-
Balance as at 31 March 2025	(83)	(5)	(46)	5	(129)

Note: "0" represents less than Rs. 1 million.



Chalasani Hospitals Private Limited

CIN: U85110AP2010PTC068262

Notes to the financial statements for the period ended 31 March 2025

(All amounts are in millions of Indian Rupees except share data or unless otherwise stated)

### 2.33 Revenue from contracts with customers:

#### Disaggregated revenue information

Set out below is the disaggregation of the Company's revenue from contracts with customers:

Particulars	For the year ended 31 March 2025	For the year ended 31 March 2024
Income from hospital services	533	473
Income from sale of pharmacy items	210	137
<b>Total revenue from contracts with customers</b>	<b>743</b>	<b>610</b>
India	743	610
Outside India	-	-
<b>Timing of revenue recognition</b>		
Services transferred over time	533	473
Goods transferred at a point of time	210	137
<b>Total revenue from contracts with customers</b>	<b>743</b>	<b>610</b>
<b>Reconciliation of revenue recognized with the contracted price is as follows:</b>		
Contract price	745	639
Less: Discounts and disallowances	(2)	(29)
<b>Total revenue from contracts with customers</b>	<b>743</b>	<b>610</b>

#### Contract balances

Particulars	As at 31 March 2025	As at 31 March 2024
Trade receivables	218	173
Contract assets - refer note 2.7(b)	10	8
Contract liabilities - refer note 2.18	2	1

Contract liability: During the financial year ended 31 March 2025, the Company has recognised revenue of Rs. 2 Mn from advance received from patients outstanding as on 31 March 2024. During the financial year ended 31 March 2024, the company has recognised revenue of Rs. 1 Mn from advance received from patients outstanding as on 31 March 2023.

Contract asset: During the financial year ended 31 March 2025, the Company has transferred Rs. 10 Mn of contract assets as at 31 March 2024 to trade receivables on completion of performance obligation. During the financial year ended 31 March 2024, the company has transferred Rs. 8 Mn of contract assets as at 31 March 2023 to trade receivables on completion of performance obligation.





2.34 Ratio Analysis and its elements

Particulars	Numerator	Denominator	As at 31 March 2025	As at 31 March 2024	% change
a) Current Ratio	Current Assets	Current Liabilities	0.49	0.62	-21.97%
b) Debt-Equity ratio *	Total Debts <sup>(1)</sup>	Shareholder's Equity	(4.71)	(2.66)	43.49%
c) Debt service coverage ratio *	Earnings for debts service <sup>(2)</sup>	Debt service <sup>(3)</sup>	(0.25)	0.04	-690.92%
d) Inventory Turnover Ratio	Cost of Goods sold	Average Inventory	6.65	8.94	-25.61%
e) Trade Receivable turnover Ratio *	Net Credit Sales <sup>(4)</sup>	Average Trade Receivables	3.80	1.88	102.17%
f) Trade Payable turnover Ratio *	Net credit Purchases <sup>(5)</sup>	Average Trade Payables	2.37	5.46	-56.50%
g) Net Capital turnover ratio *	Net Sales <sup>(6)</sup>	Working capital <sup>(7)</sup>	(2.21)	(1.65)	33.87%
h) Return on Equity Ratio *	Net profits after taxes	Average Shareholder's equity	31.21%	634.59%	-95.08%
i) Net Profit ratio *	Net profit	Net Sales <sup>(6)</sup>	-13.17%	-69.18%	-80.96%
j) Return on Capital employed *	Earnings before interest and taxes	Capital Employed <sup>(8)</sup>	-8.18%	-72.31%	-88.68%
k) Return on Investment	Interest (Finance Income)	Time weighted average investment	5.30%	5.30%	0.00%

<sup>(1)</sup> Debt includes Lease Liabilities

<sup>(2)</sup> Net profit after taxes + Non-Operating expenses

<sup>(3)</sup> Interest and lease payments + Principal Repayments

<sup>(4)</sup> Gross credit sales - sales return

<sup>(5)</sup> Gross credit purchases - purchase returns + other expenses

<sup>(6)</sup> Total sales - sales return

<sup>(7)</sup> Current assets - Current liabilities

<sup>(8)</sup> Tangible Net Worth + Total Debts + Deferred Tax Liability

\* Changes in the ratios is due to change in the business operations during the year.



### 2.35 First time adoption of Ind AS

These financial statements are the first set of Ind AS financial statements prepared by the Company. Accordingly, the Company has prepared financial statements which comply with Ind AS applicable for year ending on 31 March 2025, together with the comparative year data as at and for the year ended 31 March 2024, as described in the significant accounting policies. In preparing these financial statements, the Company's opening balance sheet was prepared as at 1 April 2023, being the Company's date of transition to Ind AS. This note explains the principal adjustments made by the Company in restating its Indian GAAP financial statements, including the balance sheet as at 1 April 2023 and the financial statements as at and for the year ended 31 March 2024.

#### Exemptions availed on first time adoption of Ind AS

Ind AS 101, First-time Adoption of Indian Accounting Standards, allows first-time adopters certain exemptions from the retrospective application of certain requirements under Ind AS. The Company has accordingly applied the following exemptions.

##### (a) Deemed Cost

Since there is no change in the functional currency, the Company has elected to continue with carrying value for all of its property, plant and equipment as recognized in its Indian GAAP financial statements as its deemed cost at the date of transition after making adjustments for de-commissioning liabilities. Accordingly the management has elected to measure all of its property, plant and equipment at their Indian GAAP carrying value.

##### (b) Compound financial instruments

When the liability component of a compound financial instrument is no longer outstanding at the date of transition to Ind AS, a first-time adopter may elect not to apply Ind AS 32, Financial Instruments: Presentation, retrospectively to split the liability and equity components of the instrument.

#### Mandatory Exemption on first-time adoption of Ind AS

##### (a) Estimates

An entity's estimates in accordance with Ind AS at the date of transition to Ind AS shall be consistent with estimates made for the same date in accordance with Indian GAAP (after adjustments to reflect any difference in accounting policies), unless there is objective evidence that those estimates were in error.

Ind AS estimates as at 1 April 2023 are consistent with the estimates as at the same date made in conformity with Indian GAAP. The Company made estimates for following items in accordance with Ind AS at the date of transition as these were not required under Indian GAAP:

- (i) Impairment of financial assets based on expected credit loss model.
- (ii) Fair valuation of compound instrument.
- (iii) Effective interest rate used in calculation of security deposit.

##### (b) Derecognition of financial assets and financial liabilities

A first-time adopter should apply the derecognition requirements in Ind AS 109, Financial Instruments, prospectively to transactions occurring on or after the date of transition. Therefore, if a first-time adopter derecognized non-derivative financial assets or non-derivative financial liabilities under its Indian GAAP as a result of a transaction that occurred before the date of transition, it should not recognize those financial assets and liabilities under Ind AS (unless they qualify for recognition as a result of a later transaction or event). A first-time adopter that wants to apply the derecognition requirements in Ind AS 109, Financial Instruments, retrospectively from a date of the entity's choosing may only do so, provided that the information needed to apply Ind AS 109, Financial Instruments, to financial assets and financial liabilities derecognized as a result of past transactions was obtained at the time of initially accounting for those transactions.

The Company has elected to apply the de-recognize provisions of Ind AS 109 prospectively from the date of transition to Ind AS.

##### (c) Classification and measurement of financial assets

Ind AS 101, First-time Adoption of Indian Accounting Standards, requires an entity to assess classification and measurement of financial assets on the basis of the facts and circumstances that exist at the date of transition to Ind AS.

#### Transition to Indian Accounting Standards (Ind AS)

These financial statements of the Company for the year ended March 31, 2025 have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015. The adoption of Ind AS was carried out in accordance with Ind AS 101, using April 1, 2023 as the transition date. Ind AS 101 requires that all Ind AS standards and interpretations that are effective for the year ended March 31, 2024, be applied consistently and retrospectively for all fiscal years presented. All applicable Ind AS have been applied consistently and retrospectively wherever required. The resulting difference between the carrying amounts of the assets and liabilities in the financial statements under both Ind AS and Previous GAAP as at the transition date have been recognised directly in equity at the transition date:

The effect of the Company's transition to Ind AS is summarized as follows:

- (i) Transition election
- (ii) Reconciliation of equity as previously reported under Indian GAAP to Ind AS
- (iii) Reconciliation of profit or loss as previously reported under Indian GAAP to Ind AS
- (iv) Adjustments to the statement of cash flows.

##### (i) Transition elections

The Company has prepared the opening Balance Sheet as per Ind AS as of April 01, 2023 (the transition date) by recognising all assets and liabilities whose recognition is required by Ind AS, not recognising items of assets or liabilities which are not permitted by Ind AS, by reclassifying items from previous GAAP to Ind AS as required under Ind AS, and applying Ind AS in measurement of recognised assets and liabilities. However, this principle is subject to certain mandatory exceptions and optional exemptions availed by the Company as detailed below:

#### Property, plant and equipment

In accordance with Ind AS transitional provisions, the Company opted to consider previous GAAP carrying value of Property, plant and equipment as deemed cost on transition date for carrying the value of Property, plant and equipment in the Ind AS financial statement.

#### Derecognition of financial assets and financial liabilities:

The Company has applied the derecognition requirements of financial assets and financial liabilities prospectively for transactions occurring on or after the transition date.



2.35 First time adoption of Ind AS (continued)

B. Reconciliation between Indian GAAP and Ind AS

Ind AS 101 requires an entity to reconcile equity and total comprehensive income for prior periods. The following table represents the equity reconciliation from previous GAAP to Ind

		As at date of transition 1 April 2023			As at 31 March 2024		
	Foot Notes	IGAAP * 01 April 2023	IND AS Impact	IND AS 01 April 2023	IGAAP * 31 March 2024	IND AS Impact	IND AS 31 March 2024
<b>ASSETS</b>							
<b>Non-current assets</b>							
Property, plant and equipment	b	231	-	231	255	(3)	258
Capital work-in-progress		38	-	38	-	-	-
Intangible assets		-	-	-	3	-	3
Intangible assets under Development		3	-	3	-	-	-
<b>Financial assets</b>							
(i) Investments		32	-	32	32	-	32
(ii) Other financial assets		40	-	40	44	-	44
Deferred tax assets, net		16	-	16	-	-	-
Non-current tax assets		73	-	73	41	-	41
Other non-current assets		41	-	41	31	-	31
<b>Total non-current assets</b>		<b>474</b>	<b>-</b>	<b>474</b>	<b>406</b>	<b>(3)</b>	<b>409</b>
<b>Current assets</b>							
Inventories		22	-	22	12	-	12
<b>Financial assets</b>							
(i) Trade receivables	a	476	-	476	173	-	173
(ii) Cash and bank balances		11	-	11	5	-	5
(iii) Bank balances other than (ii) above		-	-	-	-	-	-
(iv) Other financial assets		9	-	9	10	-	10
Other current assets		60	-	60	84	-	84
<b>Total current assets</b>		<b>578</b>	<b>-</b>	<b>578</b>	<b>284</b>	<b>-</b>	<b>284</b>
<b>Total assets</b>		<b>1,052</b>	<b>-</b>	<b>1,052</b>	<b>690</b>	<b>(3)</b>	<b>693</b>
<b>EQUITY AND LIABILITIES</b>							
<b>Equity</b>							
Equity share capital		52	-	52	53	-	53
Other equity	d	80	-	80	(321)	(3)	(318)
		<b>132</b>	<b>-</b>	<b>132</b>	<b>(268)</b>	<b>(3)</b>	<b>(265)</b>
<b>Liabilities</b>							
<b>Non-current liabilities</b>							
<b>Financial liabilities</b>							
UDIN: 25028574BMJLJG9968		487	-	487	503	-	503
(ii) Other financial liabilities		-	-	-	-	-	-
Lease Liability		-	-	-	-	-	-
Provisions		-	-	-	-	-	-
Deferred tax liability, net		-	-	-	-	-	-
<b>Total non-current liabilities</b>		<b>487</b>	<b>-</b>	<b>487</b>	<b>503</b>	<b>-</b>	<b>503</b>
<b>Current liabilities</b>							
<b>Financial liabilities</b>							
(i) Borrowings		194	-	194	202	-	202
(ii) Trade payables		-	-	-	-	-	-
(a) Total outstanding dues of micro enterprises and small enterprises		-	-	-	-	-	-
UDIN: 25028574BMJLJG9968		215	-	215	234	-	234
(iii) Other financial liabilities		3	-	3	3	-	3
Lease Liability		-	-	-	-	-	-
Other current liabilities		21	-	21	16	-	16
Provisions		-	-	-	-	-	-
Current tax liabilities		-	-	-	-	-	-
Current tax liabilities (Net)		-	-	-	-	-	-
<b>Total current liabilities</b>		<b>433</b>	<b>-</b>	<b>433</b>	<b>455</b>	<b>-</b>	<b>455</b>
<b>Total liabilities</b>		<b>920</b>	<b>-</b>	<b>920</b>	<b>958</b>	<b>-</b>	<b>958</b>
<b>Total equity and liabilities</b>		<b>1,052</b>	<b>-</b>	<b>1,052</b>	<b>690</b>	<b>(3)</b>	<b>693</b>

\* The previous GAAP figures have been reclassified to confirm to Ind AS presentation requirements for the purpose of this note.

DIN: 25028574BMJLJG9968

The notes referred to above form an integral part of the standalone financial statements.

As per our Report of even date attached

for B.NAGA BHUSHAN & CO.,  
Chartered Accountants  
Firm Reg. No. 005584S

B.Naga Bhushan  
Partner  
Membership No. 028574  
UDIN: 25028574BMJLJG9968



For and on behalf of the Board of Directors of  
Chalasani Hospitals Private Limited

Nagendra B  
Parvataneni  
Director  
DIN: 02025407

Veera Kishore  
Reddy Sane  
Director  
DIN: 03492323



Place: Hyderabad  
Date: 10.05.2025

Place: Hyderabad  
Date: 10.05.2025

**Chalasani Hospitals Private Limited**

CIN: U85110AP2010PTC068262

Notes to the financial statements for the year ended 31 March 2025 (continued)

**2.35 First time adoption of Ind AS (continued)**

**C. Reconciliation of total comprehensive income for the year ended 31 March 2024**

	Foot Notes	As at 31 March 2024	
		IGAAP* 31 March 2024	IND AS 31 March 2024
Revenue from operations		610	610
Other income		6	6
<b>Total revenue</b>		<b>616</b>	<b>616</b>
<b>Expenses</b>			
Purchase of medical consumables, drugs and surgical instruments		142	142
Decrease in inventories of medical consumables, drugs and surgical instruments		10	10
Employee benefits expense		120	120
Finance costs		71	71
Depreciation and amortisation expense	b	33	30
Other expenses		630	630
<b>Total expenses</b>		<b>1,006</b>	<b>1,003</b>
<b>Loss before Exceptional/Extra-ordinary items</b>		<b>(390)</b>	<b>(387)</b>
<b>Exceptional/ Extra-ordinary items</b>		<b>5</b>	<b>5</b>
<b>Loss before tax</b>		<b>(395)</b>	<b>(392)</b>
<b>Income-tax expense</b>			
- Current tax		-	-
- Deferred tax (credit)/ charge		16	16
- Tax pertaining to previous years		14	14
<b>Loss for the year</b>		<b>(425)</b>	<b>(422)</b>
<b>Other comprehensive income</b>			
<b>Items that will not be reclassified subsequently to profit and loss</b>			
- Re-measurement of defined benefit plans		-	-
- Income-tax effect		-	-
<b>Other comprehensive income, net of tax</b>		<b>-</b>	<b>-</b>
<b>Total comprehensive income for the year</b>		<b>(425)</b>	<b>(422)</b>

\* The previous GAAP figures have been reclassified to conform to Ind AS presentation requirements for the purpose of this note.



**2.35 First time adoption of Ind AS (continued)**

**a. Impact due to expected credit loss on trade receivables**

On transition to Ind AS, the Group recognised impairment loss on trade receivables based on the expected credit loss method as required by Ind AS 109. Consequently, trade receivables have been reduced with a corresponding decrease in retained earnings on the date of transition and there has been an incremental provision for the year ended 31 March 2023.

**b. Change in Depreciation Method from WDV to SLM under Ind AS**

Under the previous GAAP (Indian GAAP), the Company followed the Written Down Value (WDV) method of depreciation for its property, plant and equipment (PPE) in accordance with Schedule II of the Companies Act, 2013. However, upon transition to Ind AS, and in compliance with Ind AS 16 – Property, Plant and Equipment, the Company has reassessed the method of depreciation to reflect the pattern in which the asset's future economic benefits are expected to be consumed. Based on this assessment, the Company has elected to adopt the Straight Line Method (SLM) of depreciation for its PPE from the transition date.

**D. Reconciliation of other equity as at 31 March 2024 and 1 April 2023**

Particulars	INR in millions	
	As at 31 March 2024	As at 1 April 2023
Other equity under previous GAAP	(321)	80
<b>Summary of Ind AS adjustments</b>		
Impact due to transaction cost on borrowing, net of tax	-	-
Fair valuation of security deposits, net of tax	-	-
Guarantee commission for corporate guarantee given by KIMS, net of tax	-	-
Due to method of depreciation	(3)	-
Impact due to expected credit loss on trade receivables, net of tax	-	-
Arrangement containing lease, net of tax	-	-
<b>Total Ind AS adjustments</b>	<b>(3)</b>	<b>-</b>
<b>Equity under Ind AS</b>	<b>(318)</b>	<b>80</b>

**E. Cash flow statement**

Reconciliation of cash flows for the year ended 31 March 2024:

	INR in millions		
	IGAAP 31 March 2024	IND AS Impact	IND AS 31 March 2024
Net cash generated from operating activities (A)	45	3	48
Net cash used in investing activities (B)	(5)	(3)	(8)
Net cash provided by financing activities (C)	(46)	-	(46)
<b>Net increase in cash and cash equivalents (A+B+C)</b>	<b>(6)</b>	<b>-</b>	<b>(6)</b>
Cash and cash equivalents at the beginning of the year (refer note 2.7)	11	-	11
<b>Cash and cash equivalents at the end of the year</b>	<b>5</b>	<b>-</b>	<b>5</b>

As per our Report on financial statements of even date attached

for **B.NAGA BHUSHAN & CO.,**  
Chartered Accountants  
Firm Reg. No. 005584S

**B.Naga Bhushan**  
Partner

Membership No. 028574  
UDIN: 25028574BMJLJG9968

Place: Hyderabad  
Date: 10.05.2025



For and on behalf of the Board of Directors of  
**Chalasani Hospitals Private Limited**

**Nagendra B Parvataneni**  
Director  
DIN: 02025407

**Veera Kishore Reddy Sane**  
Director  
DIN: 03492323

Place: Hyderabad  
Date: 10.05.2025

Place: Hyderabad  
Date: 10.05.2025





2.36 The Company did not have any long term contracts including derivative contracts for which there were any material foreseeable losses. The Company does not have any unhedged foreign currency exposure as at 31 March 2025 and 31 March 2024.

2.37 Other Statutory Information


- (i) The Company do not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
- (ii) The Company do not have any transactions with companies struck off.
- (iii) The Company do not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.
- (iv) The Company have not traded or invested in Crypto currency or Virtual Currency during the financial year.
- (v) The Company have not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
- (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
- (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
- (vi) The Company have not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
- (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries)
- (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- (vii) The Company have not any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.
- (viii) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- (ix) The Company has not declared/paid any dividend during the year.

2.38 The Company has used accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, there are no instance of audit trail feature being tampered with, additionally the audit trail of prior year has been preserved by the Company as per the statutory requirements for record retention to the extent it was enabled and recorded in the respective year.

2.39 There were no significant adjusting events that occurred subsequent to the reporting period.

As per our report attached of even date

for B.NAGA BHUSHAN & CO.,  
Chartered Accountants  
Firm Reg. No. 005584S

  
B. Naga Bhushan  
Partner  
Membership No. 028574  
UDIN: 25028574BMJLJG9968



Place: Hyderabad  
Date: 10.05.2025

For and on behalf of the Board of Directors of  
Chalasani Hospitals Private Limited

  
Nagendra B Parvataneni  
Director  
DIN: 02025407

  
Veera Kishore Reddy  
Sane  
Director  
DIN: 03492323

Place: Hyderabad  
Date: 10.05.2025

Place: Hyderabad  
Date: 10.05.2025

